A phase II neoadjuvant trial of concurrent trastuzumab and aromatase inhibitor in postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.
Phase 2
Recruiting
- Conditions
- Postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.
- Registration Number
- JPRN-UMIN000007353
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Inflammatory breast cancer 2. Other active malignancies 3. History of cardiac infarction, valvular diseases of the heart and severe cardiac disfunction 4. Other medical conditions that could limit a patient's ability to undertake study therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical response rate, tumor reduction rate
- Secondary Outcome Measures
Name Time Method pathological CR rate, adverse event, breast conserving rate, relapse free survival, Ki-67 index changes